-Metabolic syndrome is a proatherosclerotic condition clustering cardiovascular risk factors, including glucose and lipid profile alterations. The pathophysiological mechanisms favoring atherosclerotic inflammation in the metabolic syndrome remain elusive. Here, we investigated the potential role of the antilipolytic drug acipimox on neutrophil-and monocyte-mediated inflammation in the metabolic syndrome. Acipimox (500 mg) was orally administered to metabolic syndrome patients (n ϭ 11) or healthy controls (n ϭ 8). Serum and plasma was collected before acipimox administration (time 0) as well as 2-5 h afterward to assess metabolic and hematologic parameters. In vitro, the effects of the incubation with metabolic syndrome serum were assessed on human neutrophil and monocyte migration toward the proatherosclerotic chemokine CCL3. Two to five hours after acipimox administration, a significant reduction in circulating levels of insulin and nonesterified fatty acid (NEFA) was shown in metabolic syndrome patients. At time 0 and 2 h after acipimox administration, metabolic syndrome serum increased neutrophil migration to CCL3 compared with healthy controls. No effect was shown in human monocytes. At these time points, serum-induced neutrophil migration positively correlated with serum levels of insulin and NEFA. Metabolic syndrome serum or recombinant insulin did not upregulate CCR5 expression on neutrophil surface membrane, but it increased intracellular JNK1/2 phosphorylation. Insulin immunodepletion blocked serum-induced neutrophil migration and associated JNK1/2 phosphorylation. Although mRNA expression of acipimox receptor (GPR109) was shown in human neutrophils, 5-500 M acipimox did not affect insulin-induced neutrophil migration. In conclusion, results suggest that acipimox inhibited neutrophil proatherosclerotic functions in the metabolic syndrome through the reduction in circulating levels of insulin.
atherosclerosis; insulin resistance CHRONIC ALTERATIONS IN LIPID PROFILE have been associated with high circulating levels and resistance to insulin, a condition favoring atherogenesis and acute cardiovascular events (7, 9, 20) . Importantly, the exposure to high plasma levels of free fatty acids (FFAs) might be particularly related to hyperisulinemia (20) . On the other hand, FFAs have been shown to potentially influence insulin-mediated functions by interfering with insulin receptor activation and downstream intracellular signaling pathways (20) . The increase in plasma FFA levels might be mediated by both prolonged fasting (sustained lipolysis) and excessive fat intake (24) . In the metabolic syndrome, the physiological FFA modifications are chronically exaggerated and might favor the final development of insulin resistance. Although hyperinsulinemia does not represent a diagnostic criterion of metabolic syndrome (5), insulin resistance can initiate a dangerous, vicious circle (involving inflammation and hypercoagulability), which further increases atherogenesis (6, 17) . Thus, pharmacological improvement in circulating FFA concentrations could be a very promising approach to reduce insulin resistance and associated cardiovascular risk (20) . Among several medications, the antilipolytic drug acipimox has been shown to improve insulin resistance and oral glucose tolerance in obese subjects (27). Acipimox (5-methylpyrazine-2-carboxylic acid-4-oxide) is a nicotinic acid derivative that inhibits lipolysis in adipose tissue (2) . More recently, acipimox has also been shown to bind nicotinic acid receptor (GPR109) in other tissues (30) . This discovery suggested a potential direct "pleiotropic" activity of acipimox on cell types governing atherosclerotic inflammation. The aim of the present study was to evaluate the effects of a single administration of acipimox on metabolic parameters and neutrophil and monocyte recruitment and activation in the metabolic syndrome. The direct role of acipimox on the modulation of circulating insulin levels and function on atherosclerotic neutrophilic inflammation was also investigated.
MATERIALS AND METHODS
Patients and study design. We tested acipimox treatment in a case control study between December 2009 and December 2010 at a single hospital (San Martino Hospital) in Genoa, Italy. A case was defined as a patient with metabolic syndrome [diagnosed following 2004 American Heart Association/Updated National Cholesterol Education Program (NCEP) definition criteria] (4, 5). None of patients enrolled in the study was affected by diabetes mellitus. Exclusion criteria were smoking habit, acute and chronic coronary artery and cerebrovascular disease, any cardiac arrhythmias, congestive heart failure (II, III, and IV NHYA classes), liver or renal disorders or functional abnormalities (other than microalbuminuria), acute and chronic infectious diseases, autoimmune and rheumatic diseases, cancer, endocrine diseases, inflammatory bowel diseases, anti-inflammatory or lipid-lowering medications, oral anticoagulant treatments, and hormone, cytokine, or growth factor therapies. Current medications (not modified in the 2 mo prior to enrolment) of metabolic syndrome patients were exclusively diuretics (33%), angiotensin receptor blockers (18.2%), ␤-blockers (9.1%), and calcium channel blockers (9.1%). To avoid possible pharmacological interference, these medications were stopped 1 wk prior to acipimox test. A control was defined as a healthy subject without clinical evidence of any disease or any pharmacological treatments. In healthy controls, blood, metabolic, and inflammatory laboratory parameters were in the normal ranges. Metabolic syndrome patients (n ϭ 11) and healthy controls (n ϭ 8) were submitted to the same research protocol (Fig. 1) , which was approved by the Medical Ethics Committee of San Martino Hospital. The study was conducted in compliance with the Declaration of Helsinki. After a standard meal of 600 kcal at 8 PM the day before acipimox test, subjects were instructed to remain fasted and avoid any physical activity (from moderate to strong level) until the end of the test. Only intake of water was consented. The day of the test, at 8 AM, a single dose (500 mg) of acipimox (Farmitalia Carlo Erba, Milan, Italy) was orally administrated to metabolic syndrome patients or healthy controls. Just before (time 0) and 2-5 h after acipimox administration, serum and plasma were collected to perform metabolic parameter measurements and leukocyte experiments (Fig. 1) .
Systemic marker detection. Serum insulin levels were measured by colorimetric enzyme-linked immunosorbent assay (Millipore, St. Charles, MO), following the manufacturer's instructions. Serumoxidized LDL cholesterol (ox-LDL-c) levels were measured (Mercodia, Upsala, Sweden). Plasma nonesterified fatty acid (NEFA) levels were measured by Wako NEFA C enzymatic color test (Wako Chemicals, Neuss, Germany), following manufacturer's instructions. The lower limits of detection were 2 mU/l for insulin and 1.2 mU/l for ox-LDL-c. NEFA kit ranged Յ56 mg/dl. Mean intra-and interassay coefficients of variation were Ͻ5% for both parameters. Hematological parameters were measured routinely. Glucose, triglycerides, total cholesterol, LDL cholesterol, and HDL cholesterol were measured routinely and expressed in mg/dl. The homeostasis model assessment (HOMA) index was calculated by using the formula described by Matthews et al. (13) 
Human primary neutrophil isolation. Neutrophils were isolated from human heparinized venous blood (Roche, Milan, Italy) from healthy volunteers (age 25-48 yr old) after informed and written consent was obtained. The local ethics committee approved the investigation protocol, and it was conformed to the principles outlined in the Declaration of Helsinki. Human neutrophils were isolated by heparinized venous blood by dextran sedimentation followed by centrifugation on Ficoll-Hypaque density gradient (Cedarlane Laboratories), as described previously (18) . The neutrophil isolation protocol was completed in 2 h from the blood sampling. Neutrophils were routinely Ͼ97% pure, as determined by morphological analysis of cytopreparations stained with Giemsa (Merck, Darmstadt, Germany Human primary monocyte isolation. Human monocytes were isolated from buffy coats of healthy volunteers without clinical signs of inflammatory disorders after informed consent was obtained, as described previously (15) . The protocol was approved by the local ethics committee, and it conformed with the principles outlined in the Declaration of Helsinki. Briefly, after centrifugation on FicollHypaque density gradient, mononuclear cells were collected from the interface and washed with 0.9% sodium chloride. Then, monocytes were purified from the upper interface of a hypotonic Percoll density gradient. The monocyte isolation protocol was completed in 4 h from the blood sampling. Purity of monocytes was determined by flow cytometric analysis (using anti-human CD14 Ab from BD Pharmingen, Heidelberg, Germany), confirming that Ն85% purity was achieved in all experiments.
Preparation of palmitate and oleate mixture for in vitro experiments. Palmitate and oleate mixture was prepared as described previously and used at the final concentrations of 0.2 and 0.4 mM (1). Sodium palmitate (Chem Service, West Chester, PA) and oleic acid (Wako Pure Chemical, Osaka, Japan) were dissolved to 50 mM in a solution containing 0.1 N NaOH and 70% ethanol at 70°C. Then, FFA mixture was stored at Ϫ80°C. Before use in in vitro experiments, FFA preparation was thawed and conjugated with FFA-free, low-endotoxin BSA (Sigma Chemical).
Insulin immunodepletion in metabolic syndrome serum. Serum from metabolic syndrome patients was immunodepleted of insulin as described previously for other factors (19, 23) . Serum (1 ml) was incubated with 2 g of anti-human insulin Ab (Santa Cruz Biotechnology, Santa Cruz, CA) on a rotating wheel (overnight at 4°C) and then ultracentrifuged (10,000 g, 45 min). Prior to immunodepletion, the anti-human insulin Ab was dialyzed against the buffer for 1 h at 4°C, using Slide-A-Lyzer dialysis cassettes (Pierce, Rockford, IL) to avoid a contamination of the serum samples with sodium azide. Immunoprecipitated insulin was removed, and supernatants were collected and stored at Ϫ20°C. After immunodepletion, the insulin levels in metabolic syndrome serum were measured by ultrasensitive ELISA (Mercodia, Upsala, Sweden) and found under the lower range limit (Ͻ0.15 mU/l).
Modified Boyden chamber migration assays. Neutrophils were preincubated for 30 min with control migration medium alone, undiluted serum (normal or insulin immunodepleted, obtained at different time points from metabolic syndrome patients and healthy subjects), recombinant human insulin (300 mU/l, Lilly France), or FFA mixture (0.2 or 0.4 mM palmitate/oleate). In selective experiments, neutrophils were preincubated for 1 h in the presence or the absence of different concentrations (5-500 M) of acipimox (Sigma Chemical). Then, in these experiments, after being washed three times, cells were further incubated for 30 min in the presence of migration medium or recombinant human insulin (300 mU/l; Lilly France). In both series of experiments, cells were washed with migration medium, and neutro- Fig. 1 . Study design. Treatment with acipimox was tested in metabolic syndrome patients (n ϭ 11) and healthy controls (n ϭ 8). After a standard meal of 600 kcal at 8 PM the day before acipimox test, subjects were instructed to remain fasted and avoid any physical activity until the end of the test. The day of the test, at 8 AM, a single dose (500 mg) of acipimox was orally administrated to metabolic syndrome patients and healthy controls. Just before (time 0) and 2-5 h after acipimox administration, serum and plasma were collected from subjects. phil migration toward control medium, human recombinant CCL3 (R & D Systems, Minneapolis, MN), and human recombinant CXCL8 (BioSource International, Camarillo, CA) was assessed in a 48-well microchemotaxis chamber (Neuro Probe, Gaithersburg, MD) using a 3-m-pore size, 150-m-thick cellulose ester filter (Neuro Probe). The lower wells of the chemotaxis chamber were filled with control medium, 30 nM CCL3, or 1 nM CXCL8 and the upper wells with 50 l of neutrophil suspension (2 ϫ 10 6 /ml). After incubation (45 min, 37°C), the filters were removed, fixed, and stained with Harris hematoxylin, dehydratated, cleared with xylene, and mounted in Eukitt (Kindler, Freiburg, Germany). Each condition was performed in duplicate. The distance (migration expressed in m) traveled by the leading front of cells was measured by a blinded observer at ϫ1,000 magnification. Data were expressed as migration toward control medium or chemokines (m) or, alternatively, net migration (m, obtained subtracting locomotion to control medium from locomotion to chemokine). Each condition was performed three times using neutrophils isolating from three different healthy donors.
After isolation protocol, human primary monocytes were washed three times with chemotaxis medium (RPMI containing 25 mmol/l HEPES and 1% BSA; Sigma-Aldrich). Monocytes were preincubated for 30 min with control migration medium alone, undiluted serum (from metabolic syndrome patients and healthy subjects at time 0), recombinant human insulin (at 3, 30, and 300 mU/l), or FFA (at 0.2 and 0.4 mM). Then, monocytes were washed with migration medium, and migration toward control medium, 10 nM human recombinant CCL2, or 10 nM human recombinant CCL3 (both from R & D Systems) was assessed in a 48-well microchemotaxis chamber (Neuro Probe) using a 5-m-pore size, 5-m-thick polyvinylpyrrolidone-free polycarbonate filter (Neuro Probe). Cells were seeded in upper wells, whereas medium or chemoattractant solutions were added to the lower wells. The chamber was incubated for 60 min at 37°C in a humidified atmosphere with 5% CO 2. Then, filters were removed from the chambers and stained with Diff-Quick (Baxter, Rome, Italy). Cells in five random oil immersion fields were counted at ϫ1,000 magnification (blinded observer), and the chemotaxis index was calculated from the number of cells migrated to the chemokine divided by the number of cells migrated to the medium.
Flow cytometry. Neutrophils were cultured for 30 min in the presence or absence of control migration medium alone, undiluted serum [obtained at baseline (time 0) from metabolic syndrome patients and healthy subjects], recombinant human insulin (3, 30 , and 300 mU/l; Lilly France), or FFA mixture (0.2 or 0.4 mM palmitate/ oleate) for 30 min. Then, neutrophils were washed with PBS and collected to be stained with FITC-labeled antibody anti-human CCR5 (R & D Systems Europe) as well as corresponding isotype control. CellQuest software was used for acquisition and analysis on a FACSCalibur (BD Biosciences, Heidelberg, Germany). Data were expressed as mean relative fluorescence intensities compared with expression on control medium-treated cells (defined as 100%).
Western blot analysis. After isolation, human neutrophils (1 ϫ 10 7 cells/ml) were incubated at 37°C in a humidified atmosphere of 5% CO 2 for 3 min in the presence or absence of migration medium, 300 mU/l recombinant insulin (Lilly France), serum from a metabolic syndrome patient (MS), or the same serum immunodepleted of insulin (i-MS). All conditions were tested in the presence or absence of 30 nM CCL3 for 5 min. Metabolic syndrome serum collected at time 0 (highest circulating insulin concentrations) was used. The incubations were stopped on ice, and the cells were centrifuged at 4°C. After the supernatants were removed, the pellets were lysed in 400 l of Nonidet P-40 buffer (20 mM Tris·HCl, pH 7.5, 0.15 M NaCl, 10 mM NaF, 1% Nonidet P-40, 10 g/ml glycerol, 1 mM phenylmethanesulfonyl fluoride, 10 g/ml leupeptin, 10 g/ml aprotinin, and 0.5 mM Na 3VO4 Reverse transcriptase-polymerase chain reaction. Neutrophils were isolated from human heparinized venous blood from eight healthy volunteers (age 25-36 yr old), after informed consent was obtained, by dextran sedimentation followed by centrifugation on FicollHypaque density gradient, as described previously (18) . Total RNA was extracted from neutrophils with the Nucleospin kit and oncolumn DNase digested (Macherey-Nagel, Duren, Germany), following the manufacturer's instructions. The concentration and purity of RNA were determined by spectrophotometry analysis, and cDNA was prepared from 200 ng of total RNA using the ImProm-II Reverse Transcription System (Promega, Madison, WI) as suggested by the manufacturer. As negative controls, reverse transcription experiments were realized by omitting the reverse transcriptase enzyme from the reactions. PCRs were performed using primer pairs specific for human GPR109A and GPR109B based on the nucleotide sequences available in GenBank (Table 1 ). The expression of the human ribosomal protein S13 was used as an internal control for the PCR reaction. The PCR products were separated by electrophoresis in a 1% agarose gel and visualized by UV illumination in the presence of SYBR Safe (Invitrogen, Carlsbad, CA); their molecular identity was confirmed by specific endonuclease digestion. Spearman's rank correlation coefficients were used to assess correlations between serum-induced neutrophil migration to CCL3 and circulating levels of glucose, insulin, NEFA, and ox-LDL cholesterol. All analyses were done with GraphPad InStat (San Diego, CA) software. Differences were accepted as significant when P Ͻ 0.05.
RESULTS
Patient characteristics. Metabolic syndrome was diagnosed according to the 2004 American Heart Association/Updated NCEP definition (4). Elevated glycemia (Ն100 mg/dl), blood pressure (Ն130/85 mmHg), triglycerides (Ն159 mg/dl), waist circumference (Ͼ102 cm in males or Ͼ88 cm in females), and reduced HDL cholesterol (Ͻ40 mg/dl in males or Ͻ50 mg/dl in females) were present in 72.7, 45.5, 54.5, 100.0, and 27.3% of metabolic syndrome patients, respectively. Baseline clinical characteristics and biological parameters in metabolic syndrome patients and healthy subjects are described in Table 2 . There was no significant difference between metabolic syndrome patients and healthy controls in terms of age, sex, red blood cells, white blood cells, platelets, fibrinogen, and cholesterol. As expected, other NCEP ATP III parameters, serum insulin, HOMA index, and BMI were increased in metabolic syndrome patients compared with healthy controls (4). Although all subjects had ox-LDL-c serum levels in the physiological range (10, 21) , this parameter was significantly increased in healthy controls compared with metabolic syndrome patients.
Single administration of acipimox reduces serum levels of insulin and NEFA in metabolic syndrome. A single dose (500 mg) of acipimox was orally administrated at 8 AM to metabolic syndrome patients and healthy controls. Just before (time 0) and 2-5 h after acipimox administration, serum and plasma were collected (Fig. 1) . At time 0, circulating levels of insulin and NEFA were significantly increased in metabolic syndrome patients compared with healthy controls (Fig. 2, A and B) . Serum glucose and ox-LDL-c were not modified after acipimox assumption in both groups (Fig. 3, A and B) . Conversely, insulin and NEFA were significantly reduced from time 0 in both groups (Fig. 2, A and B) . At any time point investigated, NEFA was significantly increased in metabolic syndrome patients compared with healthy controls (Fig. 2B) .
Acipimox administration was associated with the reduction of metabolic syndrome serum-induced neutrophil migration toward CCL3. At time 0 and 2 h after acipimox administration, preincubation with metabolic syndrome serum significantly increased human neutrophil migration toward CCL3 compared with serum at other time points (3-5 h after acipimox administration; Fig. 4A ). This proatherosclerotic effect (mimicking in vitro neutrophil recruitment within atherosclerotic plaques) was not observed by incubating cells with healthy control serum (Fig. 4A) .
Preincubation with serum from metabolic syndrome or healthy subjects did not induce any effect on neutrophil migration toward CXCL8 (Fig. 4B) .
Given recently shown interactions between neutrophils and monocytes in atherosclerotic inflammation (28, 29, 33) , we investigated the potential effects of acipimox administration on metabolic syndrome serum-induced monocyte migration. Human primary monocytes from healthy donors were preincubated in the presence or absence of serum from metabolic syndrome patients or healthy donors, and then cell migration Acipimox inhibits neutrophil locomotion to CCL3 in metabolic syndrome through its lowering activity on circulating levels of insulin and NEFA. To investigate by which molecular mediators acipimox reduced metabolic syndrome serum-mediated increase of neutrophil locomotion toward CCL3, we assessed potential correlations between levels of circulating metabolic parameters and serum induced on migration. At time 0 and 2 h after acipimox administration, positive correlations were found between serum-induced neutrophil migration to CCL3 and both insulin (0 h: r ϭ 0.7333, P ϭ 0.0004; 2 h: r ϭ 0.6283, P ϭ 0.0040) and NEFA levels (0 h: r ϭ 0.7895, P ϭ 0.0001; 2 h: r ϭ 0.7503, P ϭ 0.0002). No significant correlations were shown between neutrophil locomotion and glucose or ox-LDL-c (data not shown). To explore the potential role of insulin and NEFA in neutrophil migration toward CCL3, we investigated the expression of CCR5 (CCL3 receptor) in response to these stimuli. No significant upregulation on CCR5 expression on neutrophil surface membrane was shown in the presence of metabolic syndrome serum, recombinant insulin, or FFA mixture compared with control medium (Table 3 ). Then, we tested the potential effect of pretreatment with high doses of recombinant insulin or FFA on neutrophil migration toward CCL3. Confirming our recent data (14) , high levels of recombinant insulin induced neutrophil migration in response to CCL3 (Table 4) . No effect on neutrophil migration toward CCL3 was induced by pretreatment with FFA (Table 4) . Similar to what was observed in the presence of metabolic syndrome serum, recombinant insulin or FFA did not influence neutrophil migration toward CXCL8 (Table 4 ). To assess the direct effect of insulin on neutrophil migration to CCL3, we performed insulin immunodepletion in metabolic syndrome serum collected at early time points (time 0 and 2 h after acipimox administration). At these time points, pretreatment with metabolic syndrome serum increased neutrophil migration toward CCL3 (Table 5) . Conversely, after insulin immunodepletion, the same serum did not induce any effect on neutrophil migration toward CCL3 (Table  5) . Accordingly, insulin immunodepletion also abrogated met- abolic syndrome serum-mediated activation of JNK1/2 [an intracellular kinase already shown to be phosphorylated by insulin (14)] (Fig. 5, A and B) . To verify whether the beneficial effects on neutrophilic inflammation were also due to the direct activity of acipimox, we first investigated the expression of acipimox receptor (GPR109) on human primary neutrophils. Figure 6 shows that mRNA of both isoforms [GPR109A (high affinity) and GPR109B (low affinity)] of acipimox receptor was expressed in human neutrophils. No amplification products were detected in PCR reactions without reverse transcriptase (data not shown). Then, we tested recombinant insulininduced migration, preincubating neutrophils in the presence or absence of different concentrations (5-500 M) of acipimox. 
DISCUSSION
In the present article, we demonstrated that a single oral administration of acipimox (500 mg) was associated with marked improvements of the levels of insulin and NEFA in metabolic syndrome patients. These metabolic effects of acipimox were shown previously in chronic (for weeks) treatment studies enrolling non-insulin-dependent diabetes mellitus (26) , hyperlipoproteinemic patients (32), or subjects with both diseases (11) . More recently, acipimox has also been investigated in acute (a few days) treatment studies in normal and diabetic subjects, confirming promising improvements in insulin sensitivity and NEFA levels (24, 26) . In general, chronic treatments with acipimox have been used at daily doses greater (ϳ1,200 mg) than those tested in short-term studies (250 -500 mg). On the basis of these studies, we decided to administrate a single dose of 500 mg at 8 AM to fasted metabolic syndrome patients compared with healthy controls. The acute use of acipimox in metabolic syndrome patients with fasting hyperinsulinemia and high levels of NEFA represents another novelty of our study. In addition, this approach allowed us to investigate the potential direct role of this drug on insulin-mediated atherosclerotic inflammation (14, 31) . Considering recent evidence of the crucial role of neutrophils, monocytes, and their interactions in atherosclerotic inflammation (28, 29) , we focused on the pathophysiological intraplaque recruitment and activation of these leukocyte subsets. In particular, Drechsler et al. (3) recently showed that hyperlipidemia (a condition frequently observed in metabolic syndrome patients) triggered neutrophil mobilization from the bone marrow. In addition, these authors showed that neutrophilic inflammation positively correlated with the early atherogenesis in hypercholesterolemic (Ldlr Ϫ/Ϫ ) mice (3) . On the other hand, neutrophil infiltration within atherosclerotic plaques has also been shown to be strongly associated with plaque vulnerability in humans (8, 16) . Our research approach was further supported by the recent discovery of the potential "pleiotropic" activities of acipimox through the binding with its receptor GPR109 (12, 30, 34) . High levels of recombinant insulin have previously been shown to induce neutrophil recruitment toward the proinflammatory CC chemokine CCL3 that is expressed in atherosclerotic plaques (14, 16) . In addition, insulin-induced neutrophil locomotion to CCL3 was associated with the activation of intracellular JNK1/2 (14) . This pathway has recently been described to be phosphorylated by high concentrations of insulin during neutrophil locomotion (14) . Importantly, this kinase is not activated by classical neutrophil chemoattractants (such as CXCL8), which increase phosphorylation of other intracellular mitogen-activated protein kinases (14, 18) . Thus, the selective activation of JNK1/2 by insulin might represent a critical target for CCL3-induced neutrophil recruitment within atherosclerotic plaques. In the present study, we showed that insulin in serum from metabolic syndrome patients induced neutrophil migration in response to CCL3. No effect was observed on monocyte migration, suggesting that insulin selectively favors neutrophil proinflammatory functions. This observation was supported by six independent experiments: 1) Insulin levels in metabolic syndrome serum were significantly higher than those detected in healthy subjects; 2) only pretreatment with metabolic syndrome serum with elevated insulin levels (time 0 and 2 h after acipimox administration) induced neutrophil recruitment to CCL3; 3) insulin immunodepletetion in metabolic syndrome serum abrogated serum-neutrophil migration; 4) insulin serum levels positively correlated with serum-induced neutrophil migration; 5) despite a positive correlation between serum NEFA levels and serum-induced neutrophil migration, treatment with FFA mixture did not affect neutrophil migration; and 6) JNK1/2 activation (previously shown as being associated with insulininduced neutrophil migration) was increased in the presence of metabolic syndrome serum and abrogated when incubated, with the same serum insulin immunodepleted. Thus, confirming previous experiments with recombinant insulin (14) , these data strongly support the crucial role of insulin in activating inflammatory cells (such as neutrophils) in atherosclerotic disease. In particular, experiments performed with metabolic syndrome serum immunodepleted of insulin further reduced the potential involvement of other soluble mediators commonly altered in metabolic syndrome, such as adipocytokines (17) . Since neutrophil migration within atherosclerotic plaques has been shown to increase vulnerability, the inhibition of this inflammatory event could be of pathophysiological relevance to reduce acute cardiovascular events (14, 22, 35) . Therefore, we used acipimox to reduce insulin-mediated inflammation. In the 1st hour after acipimox administration, metabolic syndrome serum lost its potent priming activity on neutrophil locomotion. This effect was probably due to the associated reduction in insulin serum levels. However, a potential direct anti-inflammatory role of acipimox could not be excluded. To verify this hypothesis, we preincubated neutrophils with different concentrations (5-500 M) of acipimox reported previously as being effective in in vitro studies (27). Although mRNA GRP109 (acipimox receptor) expression was shown on naïve human neutrophils, our results demonstrated that acipimox did not directly influence recombinant insulin-insulin induced migration to CCL3. Although these data indicated that acipimox did not affect insulin-mediated neutrophil migration toward CCL3, we did not test the potential activity of this drug on other neutrophil functions. Thus, the role of acipimox in neutrophil response to infections or other inflammatory mediators remained unexplored and might be an interesting issue for another research project.
In conclusion, we showed that a single administration of acipimox was associated with the reduction of insulin and NEFA levels in metabolic syndrome patients. A decrease in insulin concentrations abrogated in vitro neutrophil recruitment toward the proatherosclerotic CC chemokine CCL3. On the other hand, acipimox did not directly interfere with insulininduced neutrophil migration. These results suggest that acipimox treatment in metabolic syndrome could be a promising approach to reduce insulin levels and its associated proatherosclerotic activities.
